SOMCHIT REYNA: Open Payments
NPI 1063843928 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,285 in 85 payments from 14 companies in 2025. Trend: 2023 $1,887 · 2024 $1,508 · 2025 $2,285
Food & beverage: $2,180Education: $105
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $626 |
| GlaxoSmithKline, LLC. | 24 | $336 |
| Incyte Corporation | 7 | $297 |
| Amgen Inc. | 12 | $240 |
| ARS Pharmaceuticals Operations, Inc. | 9 | $213 |
| Regeneron Healthcare Solutions, Inc. | 9 | $154 |
| BioCryst US Sales Co., LLC | 4 | $122 |
| SANOFI-AVENTIS U.S. LLC | 1 | $98 |
| Novartis Pharmaceuticals Corporation | 3 | $54 |
| LEO Pharma Inc. | 2 | $47 |
Products named: TEZSPIRE, FASENRA, OPZELURA, DUPIXENT, NEFFY, TRELEGY ELLIPTA, NUCALA, ORLADEYO.
Industry payments across CA — which companies pay providers there.
